September 13, 2024 11:08 AM EDTUpdated 11:50 AM

FDA approves subcutaneous Ocrevus, broadening access to Roche and Genentech blockbuster

Max Gelman

Senior Editor

The FDA on Friday approved a new formulation of Roche and Genentech’s multiple sclerosis drug Ocrevus in what they hope will broadly expand access to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA approves subcutaneous Ocrevus, broadening access to Roche and Genentech blockbuster

Max Gelman

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

All of 23andMe's independent board members resign over disagreements with CEO

Bad trip: How culture conflict and a need for cash nearly broke Lykos

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

Novartis’ Kisqali snags FDA approval to reduce recurrence in patients with early forms of breast cancer

After landing a key win in a common cancer condition, Pfizer faces a big test in Phase 3

Breaking down silos with a new quantitative approach to drug development

FDA ap­proves sub­cu­ta­neous Ocre­vus, broad­en­ing ac­cess to Roche and Genen­tech block­buster

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

FDA approves subcutaneous Ocrevus, broadening access to Roche and Genentech blockbuster